相关实验视频

Updated: Feb 28, 2026

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

A Model of Disturbed Flow-Induced Atherosclerosis in Mouse Carotid Artery by Partial Ligation and a Simple Method of RNA Isolation from Carotid Endothelium

Published on: June 22, 2010

在饮食诱导的动脉样硬化易感的血管收缩和结构性质 CB-LDL受体双击的动物模型

Kinga Shenker-Horváth^1,2, Zsolt Vass¹, Bálint Bányai³

¹Department of Morphology and Physiology, Faculty of Health Sciences, Semmelweis University, 17 Vas Street, 1088 Budapest, Hungary.

|February 27, 2026

概括

高脂肪饮食在小鼠中促进动脉样硬化,改变血管功能. 缺乏大麻素1受体 (CB1Rs) 会加剧这些变化,影响血管收缩和结构.

科学领域:

心血管科学心血管科学
药理学药理学是指药理学的学科.
遗传学是一个遗传学.

背景情况:

动脉样硬化是心血管疾病的一个关键因素.
高脂肪饮食 (HFD) 在LDL受体淘汰 (LDLR-KO) 的小鼠中诱导高胆固醇.
之前的研究表明,在缺乏1型大麻素受体 (CB1Rs) 的HFD LDLR-KO小鼠中,血管扩张得到改善.

研究的目的:

研究HFD和CB1Rs对血管收缩和结构性质的影响.
了解CB1Rs在饮食诱导的动脉样硬化和血管重塑中的作用.

主要方法:

实验使用了LDLR-CB1R双淘汰和野生型小鼠在HFD或控制饮食 (CD) 上5个月.
血管收缩性通过对大动脉片段的肌谱进行评估.
组织学分析包括油红色对斑块的染色,H&E染色,弹性质密度和光滑肌肉动蛋白 (SMA) 免疫组织化学.

主要成果:

在LDLR-KO小鼠中,HFD显著增加了斑块区域.
与WT相比,烯诱导的收缩在HFD组中升高,在CD上的CB1R-KO小鼠中更高.
在HFD中,SMA的表达增加,而在双KO-HFD小鼠中,弹性质密度最高. 亲密/介质比率降低了双倍的KO-HFD与CD相比.

结论:

在LDLR-KO小鼠中,HFD诱导的动脉样硬化涉及由CB1Rs调节的血管收缩和结构变化.
缺少CB1R导致血管收缩性增强,并影响血管重塑.
在病理条件下,CB1Rs在信号通路中发挥作用,控制血管壁厚度和弹性.

关键词:

这是一个CB1受体.对于LDL受体来说,LDL受体是非常重要的.动脉样硬化动脉样硬化这是一种内分泌大麻素 (endocannabinoid).有高脂肪的饮食.血管改造血管改造血管改造

更多相关视频

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Quantitative Analysis of Cellular Composition in Advanced Atherosclerotic Lesions of Smooth Muscle Cell Lineage-Tracing Mice

Published on: February 20, 2019

Quantification of Atherosclerosis in Mice

Quantification of Atherosclerosis in Mice

Published on: June 12, 2019

相关概念视频

Atherosclerosis III: Management

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...

Atherosclerosis I: Introduction

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...